Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

224735

	registered interest
	date	03/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Commissioning Groups: Cumbria
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20.
	tabling member constituency	Copeland
	tabling member printed	Mr Jamie Reed
	uin	226114
	answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Allocation £000</p></td><td><p>Per capita £</p></td></tr><tr><td><p>2013/14</p></td><td><p><del class="ministerial">692,122</del></p><p><ins class="ministerial">663,133</ins></p></td><td><p><del class="ministerial">1,330</del></p><p><ins class="ministerial">1,274</ins></p></td></tr><tr><td><p>2014/15</p></td><td><p>677,324</p></td><td><p>1,299</p></td></tr><tr><td><p>2015/16</p></td><td><p>685,654</p></td><td><p>1,313</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>These figures exclude running cost and Better Care Fund allocations.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 06/03/2015 14:39:07 question first ministerially corrected 19/03/2015 18:02:16 answering member 4020 label Biography information for George Freeman previous answer version 48371 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	1503 label Biography information for Mr Jamie Reed

224378

	registered interest
	date	02/03/2015
	answering body	Department for Business, Innovation and Skills
	answering dept id	26
	answering dept short name	Business, Innovation and Skills
	answering dept sort name	Business, Innovation and Skills
	hansard heading	Manufacturing Industries: Trade Competitiveness
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Innovation and Skills, what analysis he has undertaken of the reasons for the fall of drug manufacturing output in the UK since 2010; what steps he plans to take to ensure that the UK pharmaceutical industry is globally competitive; and if he will make a statement.
	tabling member constituency	Hartlepool
	tabling member printed	Mr Iain Wright
	uin	225811
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>The global pharmaceutical sector along with other industries has faced challenges in coping with the economic downturn and global squeeze on prices. Pharmaceutical global restructuring has resulted in a significant number of plant closures in Europe including in the UK due to industry-wide overcapacity in manufacturing, expiry of patents on some of the medicines manufactured in the UK and slow growth of the European pharmaceutical market over the last few years, due to budget constraints. The figures are also partly due to the pharmaceutical manufacturing industry moving from a focus on small molecules to biological products, which require different manufacturing plants and capabilities.</p><p> </p><p>We are working with the sector, in particular through the Medicines Manufacturing Industry Partnership, to respond to the opportunities and challenges it has identified. For example, the Medicines and Healthcare Products Regulatory Agency’s Innovation office published four case studies that exemplify why the UK is a leading place to introduce new manufacturing processes. We have invested significantly in national centres such as the cell therapy and precision medicine catapults. We have also invested £55m in a Cell Therapy Manufacturing Centre, £38m in the National Biologics Manufacturing Centre and £28m in a National Formulation Centre. In addition, £13 million has been invested in 7 medicines manufacturing projects under the Regional Growth Fund, leveraging an £108m in private sector investment.</p><p> </p><p> </p><p> </p><p>These initiatives will help us to develop advanced medicines manufacturing, which should enable us to build new industries in areas such as cell and gene therapies. The Life Sciences Strategy launched in December 2011 set the foundations for this renewal. We estimate that since then at least £3.5 billion inward investment into the UK has been secured, creating over 11,000 new jobs.</p><p> </p><p> </p><p> </p><p>Recently, Glaxo SmithKline and Astra Zeneca have both made significant commitments to invest in manufacturing in the UK. In addition, non UK domiciled companies have recognised the opportunity of manufacturing in the UK, with Fujifilm Diosynth, opening a new manufacturing facility in October 2013 and Eisai opening its new packaging facility in November 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/03/2015 16:14:03 answering member 4020 label Biography information for George Freeman
	tabling member	1478 label Biography information for Mr Iain Wright

224467

	registered interest
	date	02/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps the Government has taken to improve brain cancer patients' access to cancer drugs.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	225805
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for brain cancers, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies. NICE has recommended the following drugs for brain cancers as treatment options, subject to certain clinical criteria, in its technology appraisal guidance published in June 2007:</p><p> </p><p> </p><p> </p><p>- temozolomide (Temodal) for the treatment of newly diagnosed glioblastoma multiforme (GBM); and</p><p> </p><p> </p><p> </p><p>- carmustine (Gliadel) implants, for the treatment of newly diagnosed high-grade glioma.</p><p> </p><p> </p><p> </p><p>NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a drug to treat brain cancer is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund. Bevacizumab (Avastin) is available for the third line treatment of low grade paediatric gliomas through the Fund.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/03/2015 12:44:29 answering member 4020 label Biography information for George Freeman
	tabling member	1586 label Biography information for Adam Afriyie

224729

	registered interest
	date	03/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Brain: Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will fund research on using a skin test to detect hard-to-spot brain diseases.
	tabling member constituency	Upper Bann
	tabling member printed	David Simpson
	uin	226008
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>The Department's National Institute for Health Research welcomes funding applications for research into any aspect of human health, including tests for biological markers of brain diseases. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/03/2015 12:44:58 answering member 4020 label Biography information for George Freeman
	tabling member	1597 label Biography information for David Simpson

224731

	registered interest
	date	03/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: South Yorkshire
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, which schemes in Sheffield and South Yorkshire will be (a) cancelled, (b) delayed or (c) deferred as a result of the transfer of £197 million from the NHS Technology Fund budget for 2014-15 to the revenue budget.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	225998
	answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>The Department has not cancelled, delayed or deferred any agreed funding for specific capital schemes in National Health Service trusts or foundation trusts.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 225995 question first answered 06/03/2015 14:49:13 answering member 4020 label Biography information for George Freeman
	tabling member	394 label Biography information for Mr Clive Betts

224732

	registered interest
	date	03/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: South Yorkshire
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, which schemes in Sheffield and South Yorkshire will be (a) cancelled, (b) delayed or (c) deferred as a result of the transfer of £650 million from the NHS capital budget for 2014-15 to the revenue budget.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	uin	225995
	answer	answer is ministerial correction date of answer 06/03/2015 answer text <p>The Department has not cancelled, delayed or deferred any agreed funding for specific capital schemes in National Health Service trusts or foundation trusts.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 225998 question first answered 06/03/2015 14:49:13 answering member 4020 label Biography information for George Freeman
	tabling member	394 label Biography information for Mr Clive Betts

225190

	registered interest
	date	04/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the Answer of 25 February 2014, Official Report, column 279W and 28 February 2014, Official Report, column 583W, on NHS: innovation, for what reason NHS England has not published the minutes of the meetings referred to in the Answers; and if he will direct NHS England to publish those minutes.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	226401
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>The remit of patient and public engagement now falls to NHS England’s new Patient and Public Voice Assurance Group which met for the first time in June 2014.</p><p> </p><p> </p><p> </p><p>Discussions about the publication of the minutes of the Patient and Public Voice Assurance Group are ongoing.</p><p> </p><p> </p><p> </p><p>The Patient and Public Engagement Steering Group is no longer in existence and NHS England has no plans to publish the minutes of the Patient and Public Engagement Steering Group.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/03/2015 16:12:42 answering member 4020 label Biography information for George Freeman
	tabling member	4089 label Biography information for Tessa Munt

225200

	registered interest
	date	04/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cervical Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to improve cervical screening rates.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	226258
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>A leaflet sent out with every invitation for cervical screening provides women with clear, honest and balanced information about the benefits and limitations of cervical screening in order to ensure women are able to make an informed decision as to whether to have a cervical screening test or not.</p><p> </p><p> </p><p> </p><p><em>Improving Outcomes: A Strategy for Cancer</em> (January 2011) makes clear the important role that cervical screening plays in preventing cervical cancer. The strategy also notes that some groups and communities are not accessing cancer screening services. Public Health England (PHE) is working with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p> </p><p> </p><p>- Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The cervical cancer screening programme was established on the basis that it would prevent, and lead to the early diagnosis of, cervical cancer reducing the number of premature deaths.<sup><sup>[1]</sup></sup></p><p> </p><p> </p><p> </p><p>No assessment has been made of the financial consequence to the NHS on the low uptake of cervical screening. However, cost-effectiveness is a key criteria of the UK National Screening Committee recommending whether or not screening for a particular condition should take place. For example, a cost-effectiveness evaluation of the current pilot of human papillomavirus (HPV) testing as primary cervical screening is being undertaken alongside the clinical evaluation of the pilot. Cancer Research UK has estimated that, when fully implemented, HPV testing as primary screening could prevent an additional 600 cancers a year.<sup><sup>[2]</sup></sup></p><p> </p><br /><p>[1] Peto et al, The cervical cancer epidemic that screening has prevented in the UK, Lancet 2004; 364: 249-56</p><p>[2] <a href="http://msc.sagepub.com/content/early/2013/06/10/0969141313492313" target="_blank">http://msc.sagepub.com/content/early/2013/06/10/0969141313492313</a></p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226261 226264 question first answered 09/03/2015 17:47:03 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

225207

	registered interest
	date	04/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cervical Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the financial consequences for the NHS of low cervical screening rates.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	226264
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>A leaflet sent out with every invitation for cervical screening provides women with clear, honest and balanced information about the benefits and limitations of cervical screening in order to ensure women are able to make an informed decision as to whether to have a cervical screening test or not.</p><p> </p><p> </p><p> </p><p><em>Improving Outcomes: A Strategy for Cancer</em> (January 2011) makes clear the important role that cervical screening plays in preventing cervical cancer. The strategy also notes that some groups and communities are not accessing cancer screening services. Public Health England (PHE) is working with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p> </p><p> </p><p>- Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The cervical cancer screening programme was established on the basis that it would prevent, and lead to the early diagnosis of, cervical cancer reducing the number of premature deaths.<sup><sup>[1]</sup></sup></p><p> </p><p> </p><p> </p><p>No assessment has been made of the financial consequence to the NHS on the low uptake of cervical screening. However, cost-effectiveness is a key criteria of the UK National Screening Committee recommending whether or not screening for a particular condition should take place. For example, a cost-effectiveness evaluation of the current pilot of human papillomavirus (HPV) testing as primary cervical screening is being undertaken alongside the clinical evaluation of the pilot. Cancer Research UK has estimated that, when fully implemented, HPV testing as primary screening could prevent an additional 600 cancers a year.<sup><sup>[2]</sup></sup></p><p> </p><br /><p>[1] Peto et al, The cervical cancer epidemic that screening has prevented in the UK, Lancet 2004; 364: 249-56</p><p>[2] <a href="http://msc.sagepub.com/content/early/2013/06/10/0969141313492313" target="_blank">http://msc.sagepub.com/content/early/2013/06/10/0969141313492313</a></p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226258 226261 question first answered 09/03/2015 17:47:04 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi

225210

	registered interest
	date	04/03/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cervical Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of increasing cervical screening rates on (a) prevention and (b) early diagnosis of cervical cancer.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	226261
	answer	answer is ministerial correction date of answer 09/03/2015 answer text <p>A leaflet sent out with every invitation for cervical screening provides women with clear, honest and balanced information about the benefits and limitations of cervical screening in order to ensure women are able to make an informed decision as to whether to have a cervical screening test or not.</p><p> </p><p> </p><p> </p><p><em>Improving Outcomes: A Strategy for Cancer</em> (January 2011) makes clear the important role that cervical screening plays in preventing cervical cancer. The strategy also notes that some groups and communities are not accessing cancer screening services. Public Health England (PHE) is working with NHS England via the Public Health Section 7A agreement to develop a system of performance improvement through the use of performance floors, and strengthened governance for screening. The aims of the performance floors are:</p><p> </p><p> </p><p> </p><p>- Improving performance and equity of service over time by reducing the range of variation at a local level.</p><p> </p><p>- Enabling easy identification of poor performance and the setting of objectives and plans for local action, to reduce variation and improve performance.</p><p> </p><p> </p><p> </p><p>PHE will look at research provided by the STRATEGIC study (Strategies to increase cervical screening uptake at first invitation) to identify methods to help increase uptake among women. The STRATEGIC study will be publishing findings in May 2016, more details of this can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nets.nihr.ac.uk/projects/hta/0916401" target="_blank">http://www.nets.nihr.ac.uk/projects/hta/0916401</a></p><p> </p><p> </p><p> </p><p>The cervical cancer screening programme was established on the basis that it would prevent, and lead to the early diagnosis of, cervical cancer reducing the number of premature deaths.<sup><sup>[1]</sup></sup></p><p> </p><p> </p><p> </p><p>No assessment has been made of the financial consequence to the NHS on the low uptake of cervical screening. However, cost-effectiveness is a key criteria of the UK National Screening Committee recommending whether or not screening for a particular condition should take place. For example, a cost-effectiveness evaluation of the current pilot of human papillomavirus (HPV) testing as primary cervical screening is being undertaken alongside the clinical evaluation of the pilot. Cancer Research UK has estimated that, when fully implemented, HPV testing as primary screening could prevent an additional 600 cancers a year.<sup><sup>[2]</sup></sup></p><p> </p><br /><p>[1] Peto et al, The cervical cancer epidemic that screening has prevented in the UK, Lancet 2004; 364: 249-56</p><p>[2] <a href="http://msc.sagepub.com/content/early/2013/06/10/0969141313492313" target="_blank">http://msc.sagepub.com/content/early/2013/06/10/0969141313492313</a></p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 226258 226264 question first answered 09/03/2015 17:47:04 answering member 4020 label Biography information for George Freeman
	tabling member	3924 label Biography information for Yasmin Qureshi